Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Caraco Announces Stockholder Approval of Merger Agreement with Sun Pharma and Consummation of the Merger PR Newswire DETROIT, June 14, 2011 DETROIT, June 14, 2011 /PRNewswire/ -- Caraco...
Caraco Announces Merger Agreement with Sun Pharma; Caraco Public Shareholders to Receive $5.25 Cash per Share PR Newswire DETROIT, Feb. 22, 2011 DETROIT, Feb. 22, 2011 /PRNewswire/ -- Caraco...
Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2011 PR Newswire DETROIT, Jan. 30, 2011 DETROIT, Jan. 30, 2011 /PRNewswire/...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Caraco Pharmaceutical Laboratories Ltd...
Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating potential claims against members of the...
The Law Office of Abe Shainberg is investigating the Board of Directors of Caraco Pharmaceutical Laboratories Ltd. (AMEX: CPD) for possible breaches of fiduciary duty and other...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Caraco Pharmaceutical Ltd. (“Caraco” or the “Company”...
Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Caraco Pharmaceutical Laboratories, Ltd. (“Caraco” or the...
Tripp Levy PLLC, a leading national securities law firm, announces an investigation into the proposed acquisition of Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD...
Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/cpd) is investigating potential claims against the board of directors of Caraco Pharmaceutical Laboratories, Ltd. ("Caraco" or the...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
